Leukemia can show up on a PET scan, but how well it appears depends heavily on the type of leukemia involved. Acute leukemias with rapidly dividing cells tend to light up clearly, while slower-growing forms like chronic lymphocytic leukemia (CLL) often produce faint or undetectable signals. PET scans are not the primary tool used to diagnose leukemia, but they play a valuable supporting role in specific clinical situations.
How PET Scans Detect Cancer Cells
A PET scan works by tracking a radioactive sugar tracer injected into your bloodstream. Cancer cells, which burn through glucose faster than normal cells, absorb more of this tracer and glow brighter on the scan. The brightness is measured as a standardized uptake value, or SUV, with higher numbers indicating more metabolic activity.
Leukemia cells live primarily in the bone marrow rather than forming a solid tumor, which makes PET imaging trickier than it is for cancers like lymphoma or lung cancer. Still, leukemic cells in the marrow do consume extra glucose. Studies have confirmed that leukemia patients show increased tracer uptake in the vertebrae, pelvis, sternum, ribs, and limb bones, reflecting both the higher number and elevated metabolic activity of leukemic cells packed into the marrow.
Which Types of Leukemia Show Up Best
Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are the most reliably detected on PET scans. These cancers grow aggressively, and their cells divide rapidly, consuming large amounts of glucose. PET imaging identifies more disease sites than CT alone in acute leukemia, particularly in the bone marrow and smaller lymph node areas.
Chronic lymphocytic leukemia is a different story. CLL cells divide slowly and use relatively little glucose, which means they often don’t absorb enough tracer to stand out on a scan. This low metabolic activity makes PET unreliable for routine CLL detection.
However, PET scans serve a critical purpose for CLL patients in one specific scenario: detecting Richter transformation, a dangerous shift where slow-growing CLL converts into an aggressive lymphoma. A meta-analysis found that using an SUV threshold of 5 catches about 90% of these transformations, making PET one of the best tools for flagging this complication. When biopsy isn’t possible, a higher threshold of 10 provides greater confidence that the transformation has occurred, with specificity rising to about 82%.
Where PET Scans Add the Most Value
One of the strongest uses of PET imaging in leukemia is finding disease that has spread outside the bone marrow, known as extramedullary disease. In AML, leukemic cells can form tumor-like masses (sometimes called myeloid sarcomas or chloromas) in the skin, gums, lymph nodes, or organs. A prospective study called the PETAML trial found that PET/CT detected a higher prevalence of extramedullary AML than physical examination alone. Many of these deposits would have been missed without imaging. The National Comprehensive Cancer Network recommends PET/CT when extramedullary disease is suspected in AML patients.
PET scans also help assess whether treatment is working. After chemotherapy, a scan showing reduced tracer uptake in the marrow and other sites suggests the leukemia is responding. PET and CT complement each other here: PET reveals metabolic changes that indicate active disease, while CT provides the anatomic detail to pinpoint exactly where abnormalities are located.
What Can Cause Misleading Results
PET scans aren’t perfect, and false positives are a real concern. The tracer doesn’t distinguish between cancer cells and other cells that are burning extra glucose. Active infections, inflammation, and granulomatous conditions all cause immune cells like neutrophils and macrophages to consume more glucose, lighting up on the scan in ways that can mimic cancer. Elevated blood sugar levels at the time of the scan make this problem worse, because inflammatory cells absorb even more tracer under hyperglycemic conditions.
For leukemia patients specifically, growth factor medications given to boost white blood cell counts after chemotherapy can cause the bone marrow to become highly active and take up large amounts of tracer. This creates a pattern on the scan that looks like active disease even when treatment is succeeding. Timing the scan appropriately, after these medications have cleared, helps avoid this confusion.
False negatives are also possible. As mentioned, slow-growing leukemias like CLL simply don’t consume enough glucose to register. Even in acute leukemia, very early or minimal disease may fall below the scan’s detection threshold.
PET Scans vs. the Standard Diagnostic Tests
A PET scan is not how leukemia gets diagnosed. The gold standard remains a bone marrow aspiration and biopsy, where a sample of marrow is extracted and examined under a microscope for the percentage of abnormal blast cells. This procedure also allows for genetic and immune-marker testing that determines the exact subtype of leukemia, which directly shapes treatment decisions.
The diagnostic process typically starts even simpler: a complete blood count and peripheral blood smear. These basic blood tests can reveal abnormal numbers of white blood cells and identify blast cells circulating in the blood. If those results raise suspicion, the bone marrow biopsy confirms or rules out the diagnosis.
PET scans enter the picture after diagnosis, when doctors need to understand the full extent of disease, check for extramedullary involvement, evaluate treatment response, or investigate whether a chronic leukemia has transformed into something more aggressive. They provide a whole-body view that a bone marrow biopsy, which samples only one spot, cannot offer. For tracking minimal residual disease at a molecular level, though, laboratory techniques like flow cytometry remain far more sensitive than any imaging scan.
What to Expect if You’re Getting a PET Scan
If your doctor has ordered a PET scan for leukemia, you’ll typically fast for several hours beforehand to keep your blood sugar stable, since elevated glucose interferes with the tracer’s accuracy. The tracer is injected into a vein, and you’ll wait about an hour for it to circulate and be absorbed by metabolically active cells. The scan itself takes 20 to 40 minutes and is painless.
The results will show areas of increased metabolic activity throughout your body, appearing as bright spots on the images. Your medical team interprets these patterns in context, distinguishing between signals that suggest active leukemia and those caused by normal physiological activity or benign conditions like infection. In acute leukemia, the bone marrow pattern is often diffuse, meaning it lights up broadly rather than in isolated spots, which helps differentiate it from other conditions.